© 2022 MJH Life Sciences and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
2 Clarke DriveSuite 100Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
July 23, 2020
Manish A. Shah, MD, discusses the exciting updated results of the phase 2 DESTINY-Gastric01 study with fam-trastuzumab deruxtecan-nxki in HER2-expressing advanced gastric or gastroesophageal junction adenocarcinoma.
Jaffer A. Ajani, MD, discusses the potential clinical implications of fam-trastuzumab deruxtecan-nxki in gastric or gastroesophageal junction adenocarcinoma if approved by the FDA.
July 21, 2020
Experts share their insight on the efficacy and safety of trastuzumab deruxtecan in the gastric cancer space.
July 07, 2020
Salvatore Siena, MD, provides an overview of the DESTINY-CRC01 trial in DESTINY-CRC01 trial in HER2-positive metastatic colorectal cancer.
June 25, 2020
Yelena Y. Janjigian, MD, discusses updated results from the phase 2 DESTINY-Gastric01 trial in previously treated patients with HER2-positive gastric cancer.